• Something wrong with this record ?

Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial

M. Banovic, S. Putnik, BR. Da Costa, M. Penicka, MA. Deja, M. Kotrc, R. Kockova, S. Glaveckaite, H. Gasparovic, N. Pavlovic, L. Velicki, S. Salizzoni, W. Wojakowski, G. Van Camp, S. Gradinac, M. Laufer, S. Tomovic, I. Busic, M. Bojanic, A....

. 2024 ; 45 (42) : 4526-4535. [pub] 20241108

Language English Country England, Great Britain

Document type Journal Article, Randomized Controlled Trial, Multicenter Study, Comparative Study

Persistent link   https://www.medvik.cz/link/bmc25003499

Grant support
Cardiovascular Research Centre, Aalst, Belgium

BACKGROUND AND AIMS: The question of when and how to treat truly asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function is still subject to debate and ongoing research. Here, the results of extended follow-up of the AVATAR trial are reported (NCT02436655, ClinicalTrials.gov). METHODS: The AVATAR trial randomly assigned patients with severe, asymptomatic AS and LV ejection fraction ≥ 50% to undergo either early surgical aortic valve replacement (AVR) or conservative treatment with watchful waiting strategy. All patients had negative exercise stress testing. The primary hypothesis was that early AVR will reduce a primary composite endpoint comprising all-cause death, acute myocardial infarction, stroke, or unplanned hospitalization for heart failure (HF), as compared with conservative treatment strategy. RESULTS: A total of 157 low-risk patients (mean age 67 years, 57% men, mean Society of Thoracic Surgeons score 1.7%) were randomly allocated to either the early AVR group (n = 78) or the conservative treatment group (n = 79). In an intention-to-treat analysis, after a median follow-up of 63 months, the primary composite endpoint outcome event occurred in 18/78 patients (23.1%) in the early surgery group and in 37/79 patients (46.8%) in the conservative treatment group [hazard ratio (HR) early surgery vs. conservative treatment 0.42; 95% confidence interval (CI) 0.24-0.73, P = .002]. The Kaplan-Meier estimates for individual endpoints of all-cause death and HF hospitalization were significantly lower in the early surgery compared with the conservative group (HR 0.44; 95% CI 0.23-0.85, P = .012, for all-cause death and HR 0.21; 95% CI 0.06-0.73, P = .007, for HF hospitalizations). CONCLUSIONS: The extended follow-up of the AVATAR trial demonstrates better clinical outcomes with early surgical AVR in truly asymptomatic patients with severe AS and normal LV ejection fraction compared with patients treated with conservative management on watchful waiting.

Anesteziology Department 'Institute Banjica' Belgrade Serbia

Belgrade Medical School University of Belgrade Serbia

Cardiac Surgery Department University Clinical Center of Serbia Belgrade Serbia

Cardiology Department Bichat Hospital APHP and Universite Paris Cité Paris France

Cardiology Department University Clinical Center of Serbia Pasterova 2 11000 Belgrade Serbia

Cardiovascular Center OLV Hospital Aalst Belgium

Clinic of Cardiac and Vascular Diseases Institute of Clinical Medicine Faculty of Medicine Vilnius University Vilnius Lithuania

Clinical Trial Service Unit and Epidemiological Studies Unit Nuffield Department of Population Health University of Oxford Oxford UK

CorDynamix Redwood City CA USA

Department of Cardiac Surgery Institute of Cardiovascular Diseases Vojvodina Sremska Kamenica Serbia

Department of Cardiac Surgery Medical University of Silesia Katowice Poland

Department of Cardiac Surgery University of Zagreb School of Medicine and University Hospital Center Zagreb Zagreb Croatia

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiology University Clinical Center 'Bezanijska Kosa' Belgrade Serbia

Department of Cardiology University Hospital Dubrava Zagreb Croatia

Department of Internal Medicine General Hospital 'Pozarevac' Pozarevac Serbia

Division of Cardiac Surgery Cardiovascular and Thoracic Department University of Turin Turin Italy

Division of Cardiology and Structural Heart Diseases Medical University of Silesia Katowice Poland

Faculty of Medicine Hradec Králové Charles University Hradec Kralove Czech Republic

Faculty of Medicine University of Novi Sad Novi Sad Serbia

Mach Ventures Menlo Park CA USA

Sabah Al Ahmad Cardiac Center Amiri Hospital Kuwait City Kuwait

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003499
003      
CZ-PrNML
005      
20250206104358.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehae585 $2 doi
035    __
$a (PubMed)39217448
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Banovic, Marko $u Belgrade Medical School, University of Belgrade, Serbia $u Cardiology Department, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia $1 https://orcid.org/0000000200176140
245    10
$a Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial / $c M. Banovic, S. Putnik, BR. Da Costa, M. Penicka, MA. Deja, M. Kotrc, R. Kockova, S. Glaveckaite, H. Gasparovic, N. Pavlovic, L. Velicki, S. Salizzoni, W. Wojakowski, G. Van Camp, S. Gradinac, M. Laufer, S. Tomovic, I. Busic, M. Bojanic, A. Ristic, A. Klasnja, M. Matkovic, N. Boskovic, K. Zivic, M. Jovanovic, SD. Nikolic, B. Iung, J. Bartunek
520    9_
$a BACKGROUND AND AIMS: The question of when and how to treat truly asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function is still subject to debate and ongoing research. Here, the results of extended follow-up of the AVATAR trial are reported (NCT02436655, ClinicalTrials.gov). METHODS: The AVATAR trial randomly assigned patients with severe, asymptomatic AS and LV ejection fraction ≥ 50% to undergo either early surgical aortic valve replacement (AVR) or conservative treatment with watchful waiting strategy. All patients had negative exercise stress testing. The primary hypothesis was that early AVR will reduce a primary composite endpoint comprising all-cause death, acute myocardial infarction, stroke, or unplanned hospitalization for heart failure (HF), as compared with conservative treatment strategy. RESULTS: A total of 157 low-risk patients (mean age 67 years, 57% men, mean Society of Thoracic Surgeons score 1.7%) were randomly allocated to either the early AVR group (n = 78) or the conservative treatment group (n = 79). In an intention-to-treat analysis, after a median follow-up of 63 months, the primary composite endpoint outcome event occurred in 18/78 patients (23.1%) in the early surgery group and in 37/79 patients (46.8%) in the conservative treatment group [hazard ratio (HR) early surgery vs. conservative treatment 0.42; 95% confidence interval (CI) 0.24-0.73, P = .002]. The Kaplan-Meier estimates for individual endpoints of all-cause death and HF hospitalization were significantly lower in the early surgery compared with the conservative group (HR 0.44; 95% CI 0.23-0.85, P = .012, for all-cause death and HR 0.21; 95% CI 0.06-0.73, P = .007, for HF hospitalizations). CONCLUSIONS: The extended follow-up of the AVATAR trial demonstrates better clinical outcomes with early surgical AVR in truly asymptomatic patients with severe AS and normal LV ejection fraction compared with patients treated with conservative management on watchful waiting.
650    _2
$a lidé $7 D006801
650    12
$a aortální stenóza $x chirurgie $x mortalita $x terapie $7 D001024
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a konzervativní terapie $x metody $7 D000072700
650    12
$a chirurgická náhrada chlopně $x metody $7 D019918
650    _2
$a následné studie $7 D005500
650    _2
$a pozorné vyčkávání $7 D057832
650    _2
$a asymptomatické nemoci $x terapie $7 D058070
650    _2
$a výsledek terapie $7 D016896
650    _2
$a lidé středního věku $7 D008875
650    _2
$a tepový objem $x fyziologie $7 D013318
650    _2
$a aortální chlopeň $x chirurgie $7 D001021
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a cévní mozková příhoda $7 D020521
650    _2
$a avatar $7 D000095902
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Putnik, Svetozar $u Belgrade Medical School, University of Belgrade, Serbia $u Cardiac-Surgery Department, University Clinical Center of Serbia, Belgrade, Serbia
700    1_
$a Da Costa, Bruno R $u Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
700    1_
$a Penicka, Martin $u Cardiovascular Center, OLV Hospital, Aalst, Belgium
700    1_
$a Deja, Marek A $u Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland
700    1_
$a Kotrc, Martin $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kockova, Radka $u Faculty of Medicine Hradec Králové, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Glaveckaite, Sigita $u Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania $1 https://orcid.org/0000000252919954
700    1_
$a Gasparovic, Hrvoje $u Department of Cardiac Surgery, University of Zagreb School of Medicine and University Hospital Center Zagreb, Zagreb, Croatia $1 https://orcid.org/0000000224923702
700    1_
$a Pavlovic, Nikola $u Department of Cardiology, University Hospital Dubrava, Zagreb, Croatia $1 https://orcid.org/0000000191877681
700    1_
$a Velicki, Lazar $u Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia $u Department of Cardiac Surgery, Institute of Cardiovascular Diseases Vojvodina, Sremska Kamenica, Serbia
700    1_
$a Salizzoni, Stefano $u Division of Cardiac Surgery, Cardiovascular and Thoracic Department, University of Turin, Turin, Italy $1 https://orcid.org/0000000210329155
700    1_
$a Wojakowski, Wojtek $u Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
700    1_
$a Van Camp, Guy $u Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK $1 https://orcid.org/0000000256214898
700    1_
$a Gradinac, Sinisa $u Sabah Al Ahmad Cardiac Center, Amiri Hospital, Kuwait City, Kuwait
700    1_
$a Laufer, Michael $u Mach Ventures, Menlo Park, CA, USA
700    1_
$a Tomovic, Sara $u Belgrade Medical School, University of Belgrade, Serbia
700    1_
$a Busic, Ivan $u Belgrade Medical School, University of Belgrade, Serbia
700    1_
$a Bojanic, Milica $u Anesteziology Department, 'Institute Banjica', Belgrade, Serbia
700    1_
$a Ristic, Arsen $u Belgrade Medical School, University of Belgrade, Serbia $u Cardiology Department, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia $1 https://orcid.org/0000000207131180
700    1_
$a Klasnja, Andrea $u Department of Cardiology, University Clinical Center 'Bezanijska Kosa', Belgrade, Serbia
700    1_
$a Matkovic, Milos $u Belgrade Medical School, University of Belgrade, Serbia $u Cardiac-Surgery Department, University Clinical Center of Serbia, Belgrade, Serbia
700    1_
$a Boskovic, Nikola $u Cardiology Department, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia
700    1_
$a Zivic, Katarina $u Cardiology Department, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia
700    1_
$a Jovanovic, Miodrag $u Department of Internal Medicine, General Hospital 'Pozarevac', Pozarevac, Serbia
700    1_
$a Nikolic, Serge D $u CorDynamix, Redwood City, CA, USA
700    1_
$a Iung, Bernard $u Cardiology Department, Bichat Hospital APHP and Universite Paris-Cité, Paris, France
700    1_
$a Bartunek, Jozef $u Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 45, č. 42 (2024), s. 4526-4535
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39217448 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104353 $b ABA008
999    __
$a ok $b bmc $g 2263328 $s 1239506
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 45 $c 42 $d 4526-4535 $e 20241108 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
GRA    __
$p Cardiovascular Research Centre, Aalst, Belgium
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options